Advertisement

Advertisement

DE:3VG Stock Latest News

THX Pharma Nears Break-Even as Rare Disease Pivot Gains Traction

Company AnnouncementsTHX Pharma Nears Break-Even as Rare Disease Pivot Gains Traction

THX Pharma Secures Long-Term European Patent Protection for Batten-1

PremiumCompany Announcements

THX Pharma Secures Long-Term European Patent Protection for Batten-1

27d ago

THX Pharma Advances Batten-1 With Global Phase 3 Trial Filings for Juvenile Batten Disease

PremiumCompany Announcements

THX Pharma Advances Batten-1 With Global Phase 3 Trial Filings for Juvenile Batten Disease

1M ago

Theranexus Reports Semi-Annual Liquidity Contract Update

PremiumCompany Announcements

Theranexus Reports Semi-Annual Liquidity Contract Update

2y ago

Theranexus Strengthens Cash Position and Advances Drug Development Initiatives

PremiumCompany Announcements

Theranexus Strengthens Cash Position and Advances Drug Development Initiatives

2y ago

Theranexus Announces 2025 Financial Communication Agenda

PremiumCompany AnnouncementsTheranexus Announces 2025 Financial Communication Agenda

2y ago

Theranexus Announces Share and Voting Rights Information

Company Announcements

Theranexus Announces Share and Voting Rights Information

2y ago

Theranexus Publishes Shareholder Letter, Reinforcing Commitment to Rare Neurological Treatments

Company Announcements

Theranexus Publishes Shareholder Letter, Reinforcing Commitment to Rare Neurological Treatments

2y ago

Theranexus Strengthens Financial Outlook with New Agreements

PremiumCompany Announcements

Theranexus Strengthens Financial Outlook with New Agreements

2y ago

Theranexus Reports Promising Trial Results for Batten-1

PremiumCompany Announcements

Theranexus Reports Promising Trial Results for Batten-1

2y ago

Theranexus Updates Cash Position and Strategic Focus

PremiumCompany Announcements

Theranexus Updates Cash Position and Strategic Focus

2y ago

Theranexus Teams with Synerlab for Pediatric Miglustat

PremiumCompany Announcements

Theranexus Teams with Synerlab for Pediatric Miglustat

2y ago

Theranexus Reports Profit and Reduced Expenses in H1 2024

PremiumCompany AnnouncementsTheranexus Reports Profit and Reduced Expenses in H1 2024

2y ago

Theranexus Optimizes Batten-1 Trial and Secures Funding

Company Announcements

Theranexus Optimizes Batten-1 Trial and Secures Funding

2y ago

Theranexus Shows Promise in Batten Disease Study

Company Announcements

Theranexus Shows Promise in Batten Disease Study

2y ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >